SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and ...
Fintel reports that on February 21, 2024, JP Morgan downgraded their outlook for RAPT Therapeutics (NasdaqGM:RAPT) from Overweight to Neutral. As of January 19, 2024, the average one-year price target ...
As of February 1, 2023, the average one-year price target for Rapt Therapeutics is $47.12. The forecasts range from a low of $27.27 to a high of $64.05. The average price target represents an increase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results